ArticleJournal of molecular biology2011
Creating designed zinc-finger nucleases with minimal cytotoxicity.
Article in Journal of molecular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 75 citations in OpenAlex.
- Advances in gene therapy for mitochondrial genetic disorders: current status and clinical implementation challenges.Journal of translational medicine · 2025Review
- CRISPR/Cas9 mediated genome editing tools and their possible role in disease resistance mechanism.Molecular biology reports · 2022Review
- Transcriptional Activation of Biosynthetic Gene Clusters in Filamentous Fungi.Frontiers in bioengineering and biotechnology · 2022Review
- Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies.International journal of molecular sciences · 2021Review
- Genome engineering and disease modelingWorld journal of stem cells · 2021Review
- No excessive mutations in transcription activator-like effector nuclease-mediated α-1,3-galactosyltransferase knockout Yucatan miniature pigs.Asian-Australasian journal of animal sciences · 2020Article
- Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems.Clinical and translational medicine · 2020Review
- Review
- Generation of genetically-engineered animals using engineered endonucleases.Archives of pharmacal research · 2018Review
- Recent advances in the use of ZFN-mediated gene editing for human gene therapy.Cell & gene therapy insights · 2017Article
- Emerging therapies for mitochondrial disorders.Brain : a journal of neurology · 2016Review
- Origins of Programmable Nucleases for Genome Engineering.Journal of molecular biology · 2016Review
- Chapter 3 - Restoring Vision to the Blind: Gene Therapy for Vision Loss.Translational vision science & technology · 2014Article
- Gene therapy using stem cells.Cold Spring Harbor perspectives in medicine · 2014Review
- Enhanced gene disruption by programmable nucleases delivered by a minicircle vector.Gene therapy · 2014Article
- CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice.Molecular therapy. Nucleic acids · 2014Article
- Design of a colicin E7 based chimeric zinc-finger nuclease.Journal of computer-aided molecular design · 2014Article
- The I-TevI nuclease and linker domains contribute to the specificity of monomeric TALENs.G3 (Bethesda, Md.) · 2014Article
- Hybrid lentivirus-phiC31-int-NLS vector allows site-specific recombination in murine and human cells but induces DNA damage.PloS one · 2014Article
- Comparing zinc finger nucleases and transcription activator-like effector nucleases for gene targeting in Drosophila.G3 (Bethesda, Md.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Zinc-finger nucleases (ZFNs) have emerged as powerful tools for delivering a targeted genomic double-strand break (DSB) to either stimulate local homologous recombination with investigator-provided donor DNA or induce gene mutations at the site of cleavage in the absence of a donor by nonhomologous end joining both in plant cells and in mammalian cells, including human cells. ZFNs are formed by fusing zinc-finger proteins to the nonspecific cleavage domain of the FokI restriction enzyme. ZFN-mediated gene targeting yields high gene modification efficiencies (>10%) in a variety of cells and cell types by delivering a recombinogenic DSB to the targeted chromosomal locus, using two designed ZFNs. The mechanism of DSB by ZFNs requires (1) two ZFN monomers to bind to their adjacent cognate sites on DNA and (2) the FokI nuclease domains to dimerize to form the active catalytic center for the induction of the DSB. In the case of ZFNs fused to wild-type FokI cleavage domains, homodimers may also form; this could limit the efficacy and safety of ZFNs by inducing off-target cleavage. In this article, we report further refinements to obligate heterodimer variants of the FokI cleavage domain for the creation of custom ZFNs with minimal cellular toxicity. The efficacy and efficiency of the reengineered obligate heterodimer variants of the FokI cleavage domain were tested using the green fluorescent protein gene targeting reporter system. The three-finger and four-finger zinc-finger protein fusions to the REL_DKK pair among the newly generated FokI nuclease domain variants appear to eliminate or greatly reduce the toxicity of designer ZFNs to human cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.